{"id":"W4396863343","doi":"10.1177/17588359241250158","title":"Clinical activity of pembrolizumab in refractory <i>MDM2</i> -amplified advanced intimal sarcomas","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Deciphera Pharmaceuticals; Iterion Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb; Symphogen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Sarcoma; Tumor microenvironment; Refractory (planetary science); Oncology; Soft tissue sarcoma; Internal medicine; Immunotherapy; Chemotherapy; Pathology; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003629063,0.0002223911,0.0004340047,0.0002019289,0.000237374,0.0002693212,0.0001361813,0.000346551,0.0004183031],"category_scores_gemma":[0.0005910185,0.00007689756,0.0002317417,0.00009904557,0.0001932193,0.000199333,0.0001281628,0.0005563616,0.0001152353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000309012,"about_ca_system_score_gemma":0.0001529265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003489885,"about_ca_topic_score_gemma":0.0007775045,"domain_scores_codex":[0.9999034,0.00002471493,0.000012406,0.00001675985,0.00001647832,0.00002619661],"domain_scores_gemma":[0.999808,0.00007166282,0.00002707896,0.00001208227,0.00001110403,0.00007013627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02203725,0.002772748,0.2144416,0.001029308,0.0006911532,0.08386306,0.001508947,0.00515869,0.2539853,0.001004994,0.002716853,0.4107901],"study_design_scores_gemma":[0.004180491,0.06739825,0.6505708,0.0004007929,0.0009813651,0.1667821,0.0007538311,0.01662093,0.0593236,0.001805186,0.03108395,0.00009871322],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931524,0.003781681,0.0003601959,0.0002116053,0.00002090924,0.00007808808,0.00005436189,0.00001682764,0.002323815],"genre_scores_gemma":[0.9987652,0.0005720771,0.0001728739,0.0001398678,0.0000188825,0.00001429014,0.00009514445,0.000001651046,0.0002199477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0004340047,"threshold_uncertainty_score":0.002242029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04223307785315796,"score_gpt":0.4423355491676195,"score_spread":0.4001024713144615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}